Development of an integrated assay for detection of BCR-ABL RNA

Emily S. Winn-Deen, Bret Helton, Reuel Van Atta, Wendy Wong, Jeffrey Peralta, James Wang, Gregory J. Tsongalis, Dorothy Belloni, David Chan, James Eshleman, Christopher Gocke, Zsolt Jobbagy, Lan Beppu, Jerald P. Radich

Research output: Contribution to journalArticle

Abstract

Background: Current practice guidelines for managing patients with chronic myelogenous leukemia (CML) call for monitoring BCR-ABL transcript concentrations with a quantitative reverse transcription-PCR (qRT-PCR) assay. Because the available laboratory-developed assays lack consensus on the appropriate design, reporting of results, and reference intervals, we developed and evaluated an integrated BCR-ABL assay that yields standardized results for any laboratory and can be performed by technicians with no specialized training. Methods: We used the Cepheid Xpert® BCR-ABL Monitor assay to measure both BCR-ABL and ABL (endogenous control) transcripts in blood samples from CML patients and healthy individuals. The assay involves 8 manual pipetting steps, fully automated nucleic acid purification, a nested qRT-PCR step, and data analysis. Results: The BCR-ABL assay requires approximately 2 h 20 min and covers a 5-log concentration range with a lower detection limit for the BCR-ABL:ABL ratio of approximately 0.005%. Assay results were negative for 100% of the 56 known CML-negative samples (12 patients with other hematologic disorders and 44 healthy blood donors). Testing of CML-positive patients undergoing disease monitoring showed 85% agreement with negative results (17 of 20) and 100% agreement with positive results (26 of 26). An imprecision/portability study revealed no differences in performance between sites, days, instruments, and operators. Conclusions: The Xpert BCR-ABL Monitor assay provides a robust and reproducible alternative to laboratory-developed assays. Its ease of use may allow more laboratories to offer BCR-ABL testing for patients, and the short assay time enables same-day results for treating physicians.

Original languageEnglish (US)
Pages (from-to)1593-1600
Number of pages8
JournalClinical Chemistry
Volume53
Issue number9
DOIs
StatePublished - Sep 2007

Fingerprint

Assays
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
RNA
Reverse Transcription
Polymerase Chain Reaction
Transcription
Blood Donors
Practice Guidelines
Nucleic Acids
Limit of Detection
Blood
Physicians
Monitoring
Testing
Purification

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Winn-Deen, E. S., Helton, B., Van Atta, R., Wong, W., Peralta, J., Wang, J., ... Radich, J. P. (2007). Development of an integrated assay for detection of BCR-ABL RNA. Clinical Chemistry, 53(9), 1593-1600. https://doi.org/10.1373/clinchem.2007.085472

Development of an integrated assay for detection of BCR-ABL RNA. / Winn-Deen, Emily S.; Helton, Bret; Van Atta, Reuel; Wong, Wendy; Peralta, Jeffrey; Wang, James; Tsongalis, Gregory J.; Belloni, Dorothy; Chan, David; Eshleman, James; Gocke, Christopher; Jobbagy, Zsolt; Beppu, Lan; Radich, Jerald P.

In: Clinical Chemistry, Vol. 53, No. 9, 09.2007, p. 1593-1600.

Research output: Contribution to journalArticle

Winn-Deen, ES, Helton, B, Van Atta, R, Wong, W, Peralta, J, Wang, J, Tsongalis, GJ, Belloni, D, Chan, D, Eshleman, J, Gocke, C, Jobbagy, Z, Beppu, L & Radich, JP 2007, 'Development of an integrated assay for detection of BCR-ABL RNA', Clinical Chemistry, vol. 53, no. 9, pp. 1593-1600. https://doi.org/10.1373/clinchem.2007.085472
Winn-Deen ES, Helton B, Van Atta R, Wong W, Peralta J, Wang J et al. Development of an integrated assay for detection of BCR-ABL RNA. Clinical Chemistry. 2007 Sep;53(9):1593-1600. https://doi.org/10.1373/clinchem.2007.085472
Winn-Deen, Emily S. ; Helton, Bret ; Van Atta, Reuel ; Wong, Wendy ; Peralta, Jeffrey ; Wang, James ; Tsongalis, Gregory J. ; Belloni, Dorothy ; Chan, David ; Eshleman, James ; Gocke, Christopher ; Jobbagy, Zsolt ; Beppu, Lan ; Radich, Jerald P. / Development of an integrated assay for detection of BCR-ABL RNA. In: Clinical Chemistry. 2007 ; Vol. 53, No. 9. pp. 1593-1600.
@article{bfcb2ef91d7c41db942977c5f29500d1,
title = "Development of an integrated assay for detection of BCR-ABL RNA",
abstract = "Background: Current practice guidelines for managing patients with chronic myelogenous leukemia (CML) call for monitoring BCR-ABL transcript concentrations with a quantitative reverse transcription-PCR (qRT-PCR) assay. Because the available laboratory-developed assays lack consensus on the appropriate design, reporting of results, and reference intervals, we developed and evaluated an integrated BCR-ABL assay that yields standardized results for any laboratory and can be performed by technicians with no specialized training. Methods: We used the Cepheid Xpert{\circledR} BCR-ABL Monitor assay to measure both BCR-ABL and ABL (endogenous control) transcripts in blood samples from CML patients and healthy individuals. The assay involves 8 manual pipetting steps, fully automated nucleic acid purification, a nested qRT-PCR step, and data analysis. Results: The BCR-ABL assay requires approximately 2 h 20 min and covers a 5-log concentration range with a lower detection limit for the BCR-ABL:ABL ratio of approximately 0.005{\%}. Assay results were negative for 100{\%} of the 56 known CML-negative samples (12 patients with other hematologic disorders and 44 healthy blood donors). Testing of CML-positive patients undergoing disease monitoring showed 85{\%} agreement with negative results (17 of 20) and 100{\%} agreement with positive results (26 of 26). An imprecision/portability study revealed no differences in performance between sites, days, instruments, and operators. Conclusions: The Xpert BCR-ABL Monitor assay provides a robust and reproducible alternative to laboratory-developed assays. Its ease of use may allow more laboratories to offer BCR-ABL testing for patients, and the short assay time enables same-day results for treating physicians.",
author = "Winn-Deen, {Emily S.} and Bret Helton and {Van Atta}, Reuel and Wendy Wong and Jeffrey Peralta and James Wang and Tsongalis, {Gregory J.} and Dorothy Belloni and David Chan and James Eshleman and Christopher Gocke and Zsolt Jobbagy and Lan Beppu and Radich, {Jerald P.}",
year = "2007",
month = "9",
doi = "10.1373/clinchem.2007.085472",
language = "English (US)",
volume = "53",
pages = "1593--1600",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "9",

}

TY - JOUR

T1 - Development of an integrated assay for detection of BCR-ABL RNA

AU - Winn-Deen, Emily S.

AU - Helton, Bret

AU - Van Atta, Reuel

AU - Wong, Wendy

AU - Peralta, Jeffrey

AU - Wang, James

AU - Tsongalis, Gregory J.

AU - Belloni, Dorothy

AU - Chan, David

AU - Eshleman, James

AU - Gocke, Christopher

AU - Jobbagy, Zsolt

AU - Beppu, Lan

AU - Radich, Jerald P.

PY - 2007/9

Y1 - 2007/9

N2 - Background: Current practice guidelines for managing patients with chronic myelogenous leukemia (CML) call for monitoring BCR-ABL transcript concentrations with a quantitative reverse transcription-PCR (qRT-PCR) assay. Because the available laboratory-developed assays lack consensus on the appropriate design, reporting of results, and reference intervals, we developed and evaluated an integrated BCR-ABL assay that yields standardized results for any laboratory and can be performed by technicians with no specialized training. Methods: We used the Cepheid Xpert® BCR-ABL Monitor assay to measure both BCR-ABL and ABL (endogenous control) transcripts in blood samples from CML patients and healthy individuals. The assay involves 8 manual pipetting steps, fully automated nucleic acid purification, a nested qRT-PCR step, and data analysis. Results: The BCR-ABL assay requires approximately 2 h 20 min and covers a 5-log concentration range with a lower detection limit for the BCR-ABL:ABL ratio of approximately 0.005%. Assay results were negative for 100% of the 56 known CML-negative samples (12 patients with other hematologic disorders and 44 healthy blood donors). Testing of CML-positive patients undergoing disease monitoring showed 85% agreement with negative results (17 of 20) and 100% agreement with positive results (26 of 26). An imprecision/portability study revealed no differences in performance between sites, days, instruments, and operators. Conclusions: The Xpert BCR-ABL Monitor assay provides a robust and reproducible alternative to laboratory-developed assays. Its ease of use may allow more laboratories to offer BCR-ABL testing for patients, and the short assay time enables same-day results for treating physicians.

AB - Background: Current practice guidelines for managing patients with chronic myelogenous leukemia (CML) call for monitoring BCR-ABL transcript concentrations with a quantitative reverse transcription-PCR (qRT-PCR) assay. Because the available laboratory-developed assays lack consensus on the appropriate design, reporting of results, and reference intervals, we developed and evaluated an integrated BCR-ABL assay that yields standardized results for any laboratory and can be performed by technicians with no specialized training. Methods: We used the Cepheid Xpert® BCR-ABL Monitor assay to measure both BCR-ABL and ABL (endogenous control) transcripts in blood samples from CML patients and healthy individuals. The assay involves 8 manual pipetting steps, fully automated nucleic acid purification, a nested qRT-PCR step, and data analysis. Results: The BCR-ABL assay requires approximately 2 h 20 min and covers a 5-log concentration range with a lower detection limit for the BCR-ABL:ABL ratio of approximately 0.005%. Assay results were negative for 100% of the 56 known CML-negative samples (12 patients with other hematologic disorders and 44 healthy blood donors). Testing of CML-positive patients undergoing disease monitoring showed 85% agreement with negative results (17 of 20) and 100% agreement with positive results (26 of 26). An imprecision/portability study revealed no differences in performance between sites, days, instruments, and operators. Conclusions: The Xpert BCR-ABL Monitor assay provides a robust and reproducible alternative to laboratory-developed assays. Its ease of use may allow more laboratories to offer BCR-ABL testing for patients, and the short assay time enables same-day results for treating physicians.

UR - http://www.scopus.com/inward/record.url?scp=34548306597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548306597&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2007.085472

DO - 10.1373/clinchem.2007.085472

M3 - Article

C2 - 17660274

AN - SCOPUS:34548306597

VL - 53

SP - 1593

EP - 1600

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 9

ER -